Abstract: The present invention relates to dihydro-cyclopenta-isoquinoline derivatives of formula (I): processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular, disorders caused by the interaction of IgE with the Fc?RI receptor.

Abstract: The present invention relates to dihydrocyclopenta-isoquinoline-sulfonamide derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use in treating disorders caused by IgE (such as allergic responses, non-allergic mast cell responses or certain autoimmune responses), and in particular disorders caused by the interaction of IgE with the Fc?RI receptor.

Abstract: A series of substituted 4,4-difluorocyclohexyl derivatives as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

Abstract: A series of substituted fused bicyclic imidazole derivatives of formula (I), including benzimidazole derivatives and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments including inflammatory and autoimmune disorders, wherein i. a. A represents C—R1 or N; B represents C—R2 or N; D represents C—R3 or N; E represents C—R4 or N; Z represents —CH(R5)N(H)CH2R6, —CH(R5)N(H)S(O)2R6, —C(?CR5aR5b)N(H)C(O)R6, —CH(R5)R7, —CH(R5)N(H)R7 or —CH(R5)C(O)N(H)R7; R0 represents hydrogen or C1-6 alkyl.

Abstract: A series of functionalised amine derivatives of formula (I) as defined herein, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.

Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.

Abstract: Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors wherein R1 is a radical of formula -(Alk1)m-(NH)p-(Alk2)n-Q wherein m, n and p are independently 0 or 1, Alk1 and Alk2 are straight or branched chain divalent C1-C6 alkylene or C2-C6 alkenylene radicals, and Q is (i) hydrogen, except in the case where m, n and p are each 0, or (ii) an optionally substituted carbocyclic or heterocyclic group; R2 is hydrogen, C1-C3 alkyl, cyclopropyl, or —CF3; Ring A is a phenyl or 5- or 6-membered heteroaryl ring either of which is optionally substituted; Ar is a phenyl or 5- or 6-membered heteroaryl ring either of which is optionally substituted; L is —CH2—, —C(?O)—, —NH—, —O—, —S—, —SO—, —SO2—, —(CH2)2—, —CH?CH—, —OCH2—, —CH(CH3)—, or —NH—CH2—; s is 1 and W is an optionally substituted N-containing heterocyclic ring of 5 to 7 ring atoms; or s is 0 and W is an optionally substituted N-containing saturated heterocyclic ring of 5 to 7 ring atoms, or an N-con

Abstract: The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts, solvates and esters thereof. These compounds can be used to prepare pharmaceutical compositions for the treatment or prevention of disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes, obesity and sleep apnoea.

Abstract: The present invention relates to compounds of formula (I) 1

Abstract: The use of a compound of formula (1), as disclosed in the specification, wherein R1, R2, R3, R4, R5 and R6 are independently selected from hydrogen, alkyl and aryl, or pharmaceutically acceptable salts thereof, with the proviso that wherein R1 to R4 and R6 are hydrogen, R5 is not selected from CH2CH2NHSO2CH3, CH2CH2NHSO2CF3 and methyl substituted by SO2NH2, SO3H, PO3H2, CONHOH or a heterocyclic group selected from formulae (a), (b), (c), (d) and (e) in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.

Abstract: The present invention relates to indoline derivatives. These compounds are especially useful for the prevention and treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes, sleep apnea, and especially for the treatment and prevention of obesity.

Abstract: The present invention relates to indoline derivatives. These compounds are especially useful for the prevention and treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes, sleep apnea, and especially for the treatment and prevention of obesity.

Abstract: The compound of the above formula wherein R1-R5 are independently selected from hydrogen, alkyl and aryl and prodrugs thereof; and pharmaceutically acceptable salts thereof; and use of the compounds in therapy, particularly for treatment of a condition generally associated with abnormalities in glutamtergic transmission.